Navigation Links
Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Date:11/11/2011

SAN DIEGO, Nov. 11, 2011 /PRNewswire/ -- Organovo, Inc., a three dimensional biology company focused on bioprinting technology, today announced that Keith Murphy, Chairman and Chief Executive Officer, has been invited to present at the upcoming Lazard Capital Markets 8th Annual Healthcare Conference.  Mr. Murphy will present on Wednesday, November 16, 2011 at 1:30 p.m. EST.  The conference will be held at The Pierre Hotel in New York City on November 15-16, 2011.

About Organovo, Inc.

Organovo is a three dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and surgical applications. The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types.  Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine.  Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic research, using technology that has the promise to also lead to creation of therapeutic tissues.  Organovo technology leads the way in solving complex medical research problems with one overarching goal: to benefit the health and lives of patients.  http://www.organovo.com


'/>"/>
SOURCE Organovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Organovo Appoints Robert Baltera to Board
2. InterMune to Present at Canaccord Adams Conference
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
4. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
5. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
6. Bionovo to Present at Canaccord Adams Global Growth Conference
7. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
11. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... it has granted to German life sciences entrepreneurs ... and commercialization of biotechnology (collectively, the "Optionee"), an ... allogenic tumor vaccine technology (the "Technology"), including AEZS-120, ... which is ready to enter a Phase 1 ...
(Date:7/27/2015)... CHICAGO and FRANKLIN, Tenn. ... Inc. ("Capella"), a privately-owned  premier provider of health care ... companies in the U.S., today announced that its ... has signed a definitive agreement with Medical Properties ... the acquisition of Capella for $900 million in cash.  The ...
(Date:7/27/2015)... MONTREAL , July 27, 2015   ... that produces sustainable biological accelerators for farmers, has ... Patent and Trademark Office for its patent application ... that accelerate plant growth and enhance yields on ... patent relates to Inocucor,s live IN-M1 microbial consortium ...
(Date:7/27/2015)... 27, 2015 Junto Health, a company that ... and develop new technology solutions, today announced the launch ... a leader in health care policy consulting. Working together ... a collaborative innovation process while, at the same time, ... public policy, health care finance and the delivery of ...
Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4
... PHILADELPHIA Humans produce billions of clot-forming platelets every ... of them, such as with certain diseases or during ... that a single drug can induce bone marrow cells ... produce. Jae-Won Shin, a graduate student of pharmacology ...
... nanotubes, developed by MIT researchers, shows promise as an innovative ... Storing the sun,s heat in chemical form rather ... in a heavily insulated container has significant advantages, since ... periods of time without losing any of its stored energy. ...
... 13, 2011 International Isotopes Inc. (OTC Bulletin ... is pleased to announce it has selected Parsons ... management services firm, as the prime contractor for ... facility in Lea County, New Mexico.   The ...
Cached Biology Technology:Penn researchers show single drug and soft environment can increase platelet production 2Penn researchers show single drug and soft environment can increase platelet production 3MIT research update: New way to store sun's heat 2MIT research update: New way to store sun's heat 3International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility 2International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility 3International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility 4
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... particles one-billionth of a meter in size can be ... brain cancer. What's more, these nanoparticles can be used ... them, according to researchers at the University of Michigan ... Photofrin along with iron oxide into nanoparticles that would ...
... soul," corneas are the panes in those windows. They shield ... the eye's outermost lens, contributing up to 75 percent of ... at the annual meeting of the American Chemical Society, chemical ... that's finding its way into artificial corneas. It's a hydrogel, ...
... in monoclonal antibody research for oncology offers a ... of antibody therapies against solid tumors. Writing in ... http://www.interscience.wiley.com/cancer-newsroom ), a peer-reviewed journal of the American ... of cancers involve solid tumors, but only 25 ...
Cached Biology News:U-M researchers use nanoparticles to target brain cancer 2U-M researchers use nanoparticles to target brain cancer 3An artificial cornea is in sight, thanks to biomimetic hydrogels 2An artificial cornea is in sight, thanks to biomimetic hydrogels 3An artificial cornea is in sight, thanks to biomimetic hydrogels 4Report calls for improved monoclonal antibodies against solid tumors 2
... If particles in the submicron range ... development process, measurement and control of particle ... an analyzer that can reliably detect the ... The N5 Submicron Particle Size Analyzer uses ...
... High, 400 ng IgG/cm 2 (1cm2 ... Hydrophobic/Ionic , Performance Certified: Well-to-Well, CV =3% ... Well Volume: 360 µl , Packaging: 5 ... Special optically clear polystyrene formulation , High ...
... Second Mitochondria Derived Activator of Caspase/DIABLO ... pH 7.5 AVOID FREEZE/THAW CYCLES. Amino acid residues ... carboxy terminal His•Tag ® sequence was expressed ... Smac/DIABLO is released along with cytochrome c ...
... JASCO offers a dedicated system for ... modular LC-1500 series of HPLC instrumentation. JASCO ... enhance the capability of the system: ,- ... chromatography and extraction procedures using carbon dioxide ...
Biology Products: